What is GWAS, and how is it used in ADHD research?

PostedOctober 7, 2025

UpdatedOctober 10, 2025

ByMy Patient Advice

Author: Victoria Rowe, MSc | Reviewed by: Dr. Rebecca Fernandez, MBBS

A genome-wide association study or ADHD GWAS is a powerful research tool used to identify genetic variants associated with attention deficit hyperactivity disorder. Rather than focusing on a single gene, GWAS scans the entire genome of thousands of individuals to find common genetic markers that may contribute to the condition.

In ADHD research, GWAS has transformed how scientists understand the genetics behind symptoms like inattention, impulsivity, and emotional dysregulation. By comparing the genomes of individuals with ADHD to those without, researchers can identify specific regions of DNA that show up more frequently in affected individuals. This method helps uncover subtle genetic influences that may otherwise go undetected.

Why GWAS Matters in ADHD Genetics

Here is how GWAS helps shape the current landscape of ADHD diagnosis and treatment:

Broad genetic insights

Unlike older research methods that studied one gene at a time, GWAS enables scientists to look at thousands or even millions of genetic variations simultaneously. This approach has uncovered associations with genes involved in dopamine signalling, neural development, and synaptic plasticity.

Risk profiling and early detection

ADHD GWAS findings may one day help identify children at higher genetic risk, allowing for earlier monitoring and intervention. While not yet a diagnostic tool, this research could guide clinical attention in the future.

Better-targeted treatments

By linking symptoms to specific genetic profiles, researchers can start to explore more personalised treatment strategies from medication selection to behavioural therapies based on a person’s unique genetic make-up. Visit providers like ADHD Certify for personal consultations informed by the latest research.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Genetic studies and biomarkers.

Victoria Rowe, MSc

Author

Victoria Rowe is a health psychologist with a Master’s in Health Psychology and a BS in Applied Psychology. She has experience as a school psychologist, conducting behavioural assessments, developing individualized education plans (IEPs), and supporting children’s mental health. Dr. Rowe has contributed to peer-reviewed research on mental health, including studies on anxiety disorders and the impact of COVID-19 on healthcare systems. Skilled in SPSS, Minitab, and academic writing, she is committed to advancing psychological knowledge and promoting well-being through evidence-based practice.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Rebecca Fernandez, MBBS

Reviewer

Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence-based approaches such as CBT, ACT, and mindfulness-based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewer's privacy.